Total Cholesterol Levels in Men with Schizophrenia Receiving Risperidone and Haloperidol Treatment
DOI:
https://doi.org/10.3889/oamjms.2021.6333Keywords:
Schizophrenia, Total cholesterol, Antipsychotic risperidone and haloperidolAbstract
AIM: The objectives of the study were to compare total cholesterol levels in men with schizophrenia receiving risperidone and haloperidol treatment.
METHODS: We conducted on treatment analysis experiment study involving 30 subjects who received risperidone and 30 subjects who received haloperidol. Total cholesterol levels were examined at week 0 and week 8.
RESULTS: There were no statistically significant differences in baseline characteristics. At week 8, mean of total cholesterol level in the risperidone group was 207.23 ± 21.49 compared to 188.17 ± 17.00 in the haloperidol group. A difference of 19.06 ± 5.00 (95% CI 9.05–29.08) was observed, which is statistically significant (p < 0.001).
CONCLUSIONS: There was a statistically significant increase in total cholesterol levels in men with schizophrenia receiving risperidone compared to haloperidol.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Thaker GK. Schizophrenia: Phenotypeof psychosis. In: Sadock BJ, Sadock VA, editors. Penyunting Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 10th ed., Vol. 1. Philadelphia, PA: Lippincott Williams and Wilkins; 2017. p. 3880-98.
Sadock BJ, Sadock VA. Scizophrenia spectrum and other psychotic disorder. In: Sadock BJ, Sadock VA, editors. Penyunting Kaplan and Sadock’s Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 11th ed. Philadelphia, PA: Lippincott Willams and Wilkins; 2014. https://doi.org/10.1097/00004850-198907000-00008 DOI: https://doi.org/10.1097/00004850-198907000-00008
Sadock BJ, Sadock VA. Medical health in schizophrenia. In: Sadock BJ, Sadock VA. Penyunting Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 11th ed., Vol. 1. Philadelphia, PA: Lippincott Williams and Wilkins; 2017. p. 3947-73. https://doi.org/10.4067/s0717-92272002000300011 DOI: https://doi.org/10.4067/S0717-92272002000300011
Solberg DK, Bentsen H, Refsum H, Andreassen OA. Lipid profiles in schizophrenia associated with clinical traits: A five year follow-up study. BMC Psychiatry. 2016;16:299. https://doi.org/10.1186/s12888-016-1006-3 DOI: https://doi.org/10.1186/s12888-016-1006-3
Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem. 2009;9(4):1291-7. https://doi.org/10.2174/156802609789869628 DOI: https://doi.org/10.2174/156802609789869628
Marder SR, Davis MC. Second generation antipsychotic. In: Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 11th ed., Vol. 1. Philladephia, PA: Lippincott Williams and Wilkins; 2017. p. 8104-42.
Connolly M, Kelly C. Lifestyle and physical health in schizophrenia. Adv Psychiatr Treatment. 2005;11:125-32. DOI: https://doi.org/10.1192/apt.11.2.125
Dahlan MS. In: Dahlan MS, editor. Langkah-langkah Membuat Proposal Penelitian Bidang Kedokteran dan Kesehatan. 2nd ed. Jakarta: CV Sagung Seto; 2009.
Huang TL, Chen JF. Serum lipid profiles and schizophrenia: Effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res. 2005;80(1):55-9. https://doi.org/10.1016/j.schres.2005.05.001 DOI: https://doi.org/10.1016/j.schres.2005.05.001
Roohafza H, Khani A, Afshar H, Garakyaraghi M, Amirpour A, Ghodsi B. Lipid profile in antipsychotic drug users: A comparative study. ARYA Atheroscler. 2013;9(3):198-202. PMid:23766777
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Agusmita Agusmita, Bahagia Loebis, Muhammad Surya Husada, Elmeida Effendy (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
